Susmed

Susmed EBIT per Share

The EBIT per Share of Susmed (4263.T) as of Oct 29, 2026 is -19.56 JPY. In the previous year, EBIT per Share was -17.77 JPY — a change of 10.06% (lower).

EBIT per Share

-19.56JPY

YoY

10.06%

Last updated:

EBIT per Share of Susmed is 2026 -19.56 JPY. EBIT per Share of Susmed was 2025 -17.77 JPY. It decreases by 10.06% lower compared to the previous year.

The Susmed EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-2.97 JPY
Jan 1, 2024
-21.73 JPY
Jan 1, 2025
-17.77 JPY
Jan 1, 2026
-19.56 JPY
Jan 1, 2027 (e)
-8.88 JPY
Jan 1, 2028 (e)
2.78 JPY
Jan 1, 2029 (e)
169.32 JPY
Jan 1, 2030 (e)
212.28 JPY
The Susmed EBIT per Share history
YEAREBIT per ShareYoY
est212.28JPY+25.37%
est169.32JPY+5,990.91%
est2.78JPY-131.29%
est-8.88JPY-54.58%
-19.56JPY+10.06%
-17.77JPY-18.21%
-21.73JPY+630.85%
-2.97JPY-79.15%
-14.26JPY-33.24%
-21.36JPY+124.29%
-9.52JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Susmed Stock analysis

What does Susmed do? SUSMED, Inc. generates revenue through its DTx Product segment, which develops application software for treating insomnia, breast cancer, and chronic kidney diseases. The DTx Platform segment provides clinical trial systems, machine learning analysis systems, and DTx development support services. The company's primary customers are healthcare providers and pharmaceutical companies seeking digital therapeutics solutions. SUSMED targets the healthcare technology market with its specialized software and support services for disease treatment and clinical research. The DTx Product segment focuses on creating therapeutic applications for specific medical conditions, while the DTx Platform segment offers infrastructure for clinical trials and machine learning analysis. SUSMED's business model relies on selling both its proprietary software products and platform services to healthcare institutions and pharmaceutical firms. The company's revenue streams include software licensing, system subscriptions, and development support fees. SUSMED's products are designed to address chronic conditions like insomnia and breast cancer, with additional focus on chronic kidney diseases. The DTx Platform serves as a comprehensive solution for clinical trial management and machine learning-driven analysis, supporting pharmaceutical companies in their drug development processes. The company's services are tailored to meet the needs of healthcare technology providers and pharmaceutical developers. Susmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Susmed stock

EBIT per Share of Susmed is -19.56 JPY in 2026.

EBIT per Share of Susmed changed from -17.77 JPY to -19.56 JPY, representing a 10.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Susmed since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Susmed

All Key Metrics — Susmed